These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 12044585)

  • 1. Postprandial lipemia--effect of lipid-lowering drugs.
    Karpe F
    Atheroscler Suppl; 2002 May; 3(1):41-6. PubMed ID: 12044585
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison in patients with type 2 diabetes of fibric acid versus hepatic hydroxymethyl glutaryl-coenzyme a reductase inhibitor treatment of combined dyslipidemia.
    McLaughlin T; Abbasi F; Lamendola C; Leary E; Reaven GM
    Metabolism; 2002 Oct; 51(10):1355-9. PubMed ID: 12370858
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A head-to-head comparison of the cost effectiveness of HMG-CoA reductase inhibitors and fibrates in different types of primary hyperlipidemia.
    Perreault S; Hamilton VH; Lavoie F; Grover S
    Cardiovasc Drugs Ther; 1997 Jan; 10(6):787-94. PubMed ID: 9110123
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of statins on postprandial lipemia.
    Kolovou GD; Anagnostopoulou KK; Salpea KD; Daskalopoulou SS; Mikhailidis DP
    Curr Drug Targets; 2007 Apr; 8(4):551-60. PubMed ID: 17430126
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of dyslipoproteinemia in the metabolic syndrome.
    Steinmetz A; Fenselau S; Schrezenmeir J
    Exp Clin Endocrinol Diabetes; 2001; 109(4):S548-59. PubMed ID: 11453042
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term safety and efficacy of combination gemfibrozil and HMG-CoA reductase inhibitors for the treatment of mixed lipid disorders.
    Murdock DK; Murdock AK; Murdock RW; Olson KJ; Frane AM; Kersten ME; Joyce DM; Gantner SE
    Am Heart J; 1999 Jul; 138(1 Pt 1):151-5. PubMed ID: 10385779
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current and future treatment of hyperlipidemia: the role of statins.
    Farnier M; Davignon J
    Am J Cardiol; 1998 Aug; 82(4B):3J-10J. PubMed ID: 9737640
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selection of appropriate type and intensity of lipid-lowering therapy.
    Tikkanen MJ
    Curr Opin Lipidol; 1995 Dec; 6(6):360-4. PubMed ID: 8750248
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimal management of combined dyslipidemia: what have we behind statins monotherapy?
    Tenenbaum A; Fisman EZ; Motro M; Adler Y
    Adv Cardiol; 2008; 45():127-153. PubMed ID: 18230960
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic effects of fibrates in postprandial lipemia.
    Kolovou GD; Kostakou PM; Anagnostopoulou KK; Cokkinos DV
    Am J Cardiovasc Drugs; 2008; 8(4):243-55. PubMed ID: 18690758
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Efficacy and safety of combined statin-fenofibrates therapy compared with monotherapy in patients with mixed hyperlipidemia and high risk of coronary heart disease].
    Kłosiewicz-Latoszek L; Respondek W; Białobrzeska-Paluszkiewicz J; Grzybowska B; Jakóbisiak-Ostasz B; Stolarska I
    Pol Merkur Lekarski; 2003 Jul; 15(85):42-6. PubMed ID: 14593958
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Normocholesterolaemic dysslipidaemia: is there a role for fibrates?
    Hamilton-Craig I
    Med J Aust; 2001 Jun; 174(11):610; author reply 611. PubMed ID: 11453341
    [No Abstract]   [Full Text] [Related]  

  • 13. The effects of lipid-lowering agents on acute renal allograft rejection.
    Kasiske BL; Heim-Duthoy KL; Singer GG; Watschinger B; Germain MJ; Bastani B
    Transplantation; 2001 Jul; 72(2):223-7. PubMed ID: 11477342
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effects of medications used for the management of dyslipidemia on postprandial lipemia.
    Tentolouris N; Eleftheriadou I; Katsilambros N
    Curr Med Chem; 2009; 16(2):203-17. PubMed ID: 19149572
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Statins (HMG-CoA reductase inhibitors)].
    Gotoda T
    Nihon Rinsho; 2006 Nov; 64(11):2113-8. PubMed ID: 17087305
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Statins for stroke: the second story?
    Plutzky J; Ridker PM
    Circulation; 2001 Jan; 103(3):348-50. PubMed ID: 11157683
    [No Abstract]   [Full Text] [Related]  

  • 17. Lipid-lowering effects of ezetimibe and simvastatin in combination.
    Ijioma N; Robinson JG
    Expert Rev Cardiovasc Ther; 2011 Feb; 9(2):131-45. PubMed ID: 21453210
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of statins vs. non-statin lipid-lowering therapy on bone formation and bone mineral density biomarkers in patients with hyperlipidemia.
    Chuengsamarn S; Rattanamongkoulgul S; Suwanwalaikorn S; Wattanasirichaigoon S; Kaufman L
    Bone; 2010 Apr; 46(4):1011-5. PubMed ID: 20045497
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of fibrates in clinical practice: Queensland Lipid Group consensus recommendations.
    Hamilton-Craig I; Kostner KM; Woodhouse S; Colquhoun D
    Int J Evid Based Healthc; 2012 Sep; 10(3):181-90. PubMed ID: 22925614
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of lipid-modulating drugs in complicated course of coronary heart disease.
    Gratsianskii NA; Vaulin NA
    Bull Exp Biol Med; 2007 Sep; 144(3):438-46. PubMed ID: 18457052
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.